217 related articles for article (PubMed ID: 15735062)
1. Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice.
Aono Y; Nishioka Y; Inayama M; Ugai M; Kishi J; Uehara H; Izumi K; Sone S
Am J Respir Crit Care Med; 2005 Jun; 171(11):1279-85. PubMed ID: 15735062
[TBL] [Abstract][Full Text] [Related]
2. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
Distler JH; Jüngel A; Huber LC; Schulze-Horsel U; Zwerina J; Gay RE; Michel BA; Hauser T; Schett G; Gay S; Distler O
Arthritis Rheum; 2007 Jan; 56(1):311-22. PubMed ID: 17195235
[TBL] [Abstract][Full Text] [Related]
3. Role of alpha1-acid glycoprotein in therapeutic antifibrotic effects of imatinib with macrolides in mice.
Azuma M; Nishioka Y; Aono Y; Inayama M; Makino H; Kishi J; Shono M; Kinoshita K; Uehara H; Ogushi F; Izumi K; Sone S
Am J Respir Crit Care Med; 2007 Dec; 176(12):1243-50. PubMed ID: 17717205
[TBL] [Abstract][Full Text] [Related]
4. [Effect of imatinib mesylate on bleomycin-induced pulmonary fibrosis in mice].
Li L; Li YQ
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2007 Apr; 19(4):229-32. PubMed ID: 17448279
[TBL] [Abstract][Full Text] [Related]
5. Effect of nilotinib on bleomycin-induced acute lung injury and pulmonary fibrosis in mice.
Rhee CK; Lee SH; Yoon HK; Kim SC; Lee SY; Kwon SS; Kim YK; Kim KH; Kim TJ; Kim JW
Respiration; 2011; 82(3):273-87. PubMed ID: 21659722
[TBL] [Abstract][Full Text] [Related]
6. Effects of the protein kinase inhibitor, imatinib mesylate, on epithelial/mesenchymal phenotypes: implications for treatment of fibrotic diseases.
Vittal R; Zhang H; Han MK; Moore BB; Horowitz JC; Thannickal VJ
J Pharmacol Exp Ther; 2007 Apr; 321(1):35-44. PubMed ID: 17218487
[TBL] [Abstract][Full Text] [Related]
7. Antifibrotic effects of focal adhesion kinase inhibitor in bleomycin-induced pulmonary fibrosis in mice.
Kinoshita K; Aono Y; Azuma M; Kishi J; Takezaki A; Kishi M; Makino H; Okazaki H; Uehara H; Izumi K; Sone S; Nishioka Y
Am J Respir Cell Mol Biol; 2013 Oct; 49(4):536-43. PubMed ID: 23642017
[TBL] [Abstract][Full Text] [Related]
8. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms.
O'Sullivan S; Naot D; Callon K; Porteous F; Horne A; Wattie D; Watson M; Cornish J; Browett P; Grey A
J Bone Miner Res; 2007 Nov; 22(11):1679-89. PubMed ID: 17663639
[TBL] [Abstract][Full Text] [Related]
9. Prevention of bleomycin-induced pulmonary fibrosis by a novel antifibrotic peptide with relaxin-like activity.
Pini A; Shemesh R; Samuel CS; Bathgate RA; Zauberman A; Hermesh C; Wool A; Bani D; Rotman G
J Pharmacol Exp Ther; 2010 Dec; 335(3):589-99. PubMed ID: 20826567
[TBL] [Abstract][Full Text] [Related]
10. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
Basciani S; Brama M; Mariani S; De Luca G; Arizzi M; Vesci L; Pisano C; Dolci S; Spera G; Gnessi L
Cancer Res; 2005 Mar; 65(5):1897-903. PubMed ID: 15753388
[TBL] [Abstract][Full Text] [Related]
11. Blockade of platelet-derived growth factor receptor-β, not receptor-α ameliorates bleomycin-induced pulmonary fibrosis in mice.
Kishi M; Aono Y; Sato S; Koyama K; Azuma M; Abe S; Kawano H; Kishi J; Toyoda Y; Okazaki H; Ogawa H; Uehara H; Nishioka Y
PLoS One; 2018; 13(12):e0209786. PubMed ID: 30596712
[TBL] [Abstract][Full Text] [Related]
12. Gefitinib attenuates murine pulmonary fibrosis induced by bleomycin.
Wang P; Tian Q; Liang ZX; Yang Z; Xu SF; Sun JP; Chen LA
Chin Med J (Engl); 2010 Aug; 123(16):2259-64. PubMed ID: 20819676
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model.
Chaudhary NI; Schnapp A; Park JE
Am J Respir Crit Care Med; 2006 Apr; 173(7):769-76. PubMed ID: 16415276
[TBL] [Abstract][Full Text] [Related]
14. Imatinib mesylate inhibits fibrogenesis in asbestos-induced interstitial pneumonia.
Vuorinen K; Gao F; Oury TD; Kinnula VL; Myllärniemi M
Exp Lung Res; 2007 Sep; 33(7):357-73. PubMed ID: 17849262
[TBL] [Abstract][Full Text] [Related]
15. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis.
Wollin L; Maillet I; Quesniaux V; Holweg A; Ryffel B
J Pharmacol Exp Ther; 2014 May; 349(2):209-20. PubMed ID: 24556663
[TBL] [Abstract][Full Text] [Related]
16. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis.
Daniels CE; Wilkes MC; Edens M; Kottom TJ; Murphy SJ; Limper AH; Leof EB
J Clin Invest; 2004 Nov; 114(9):1308-16. PubMed ID: 15520863
[TBL] [Abstract][Full Text] [Related]
17. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis.
Oku H; Shimizu T; Kawabata T; Nagira M; Hikita I; Ueyama A; Matsushima S; Torii M; Arimura A
Eur J Pharmacol; 2008 Aug; 590(1-3):400-8. PubMed ID: 18598692
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effect of emodin on bleomycin-induced pulmonary fibrosis in mice.
Chen XH; Sun RS; Hu JM; Mo ZY; Yang ZF; Jin GY; Guan WD; Zhong NS
Clin Exp Pharmacol Physiol; 2009 Feb; 36(2):146-53. PubMed ID: 18785980
[TBL] [Abstract][Full Text] [Related]
19. Role of platelet-derived growth factor/platelet-derived growth factor receptor axis in the trafficking of circulating fibrocytes in pulmonary fibrosis.
Aono Y; Kishi M; Yokota Y; Azuma M; Kinoshita K; Takezaki A; Sato S; Kawano H; Kishi J; Goto H; Uehara H; Izumi K; Nishioka Y
Am J Respir Cell Mol Biol; 2014 Dec; 51(6):793-801. PubMed ID: 24885373
[TBL] [Abstract][Full Text] [Related]
20. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis.
Akhmetshina A; Venalis P; Dees C; Busch N; Zwerina J; Schett G; Distler O; Distler JH
Arthritis Rheum; 2009 Jan; 60(1):219-24. PubMed ID: 19116940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]